Patents by Inventor Xiaoling Zheng

Xiaoling Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240347131
    Abstract: A cancer detection model and a construction method therefor, and a reagent kit, relating to the technical field of cancer detection. The method comprises: performing whole genome sequencing on plasma free DNA to mine nucleosome distribution features, terminal sequence features, and fragment size distribution features that can be applied to cancer detection; constructing classification models of the three indicators to obtain prediction scores of each indicator for a sample; then integrating these scores using a logistic regression model, and adding copy number variation feature information to obtain an ultimate classification and prediction model.
    Type: Application
    Filed: March 8, 2022
    Publication date: October 17, 2024
    Applicant: BERRY ONCOLOGY CO., LTD.
    Inventors: Qingzheng ZHANG, Lu ZHENG, Fuming SUN, Jian BAI, Yin WANG, Xiaoling LI, Lin WU
  • Patent number: 12049270
    Abstract: Techniques are described for managing redundant steering system for a vehicle. A method includes sending a first control command that instructs a first motor coupled to a steering wheel in a steering system to steer a vehicle, receiving, after sending the first control command, a speed of the vehicle, a yaw rate of the vehicle, and a steering position of the steering wheel, determining, based at least on the speed and the yaw rate, an expected range of steering angles that describes values within which the first motor is expected to steer the vehicle based on the first control command, and upon determining that the steering position of a steering wheel is outside the expected range of steering angles, sending a second control command that instructs a second motor coupled to the steering wheel in the steering system to steer the vehicle.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: July 30, 2024
    Assignee: TUSIMPLE, INC.
    Inventors: Kaixin Zheng, Xiaoling Han, Zehua Huang
  • Patent number: 12037648
    Abstract: The present disclosure belongs to the field of livestock molecular biotechnology, and provides kits and methods for pedigree division and paternity testing of domestic pigs. The kits and methods specifically select 14 SSR loci of domestic pigs, especially Anqing six-end-white pigs, and synthesize primers for corresponding loci. Through capillary electrophoresis detection of the ear tissue DNA of 98 Anqing six-end-white pigs, the count of effective alleles, heterozygosity, polymorphism information content, and genetic distance, and exclusion probability at each locus are calculated, the pedigree division of domestic pigs, especially Anqing six-end-white pigs, and paternity testing are conducted. The cumulative exclusion probability of 14 microsatellite loci is 99%.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: July 16, 2024
    Assignee: ANHUI AGRICULTURAL UNIVERSITY
    Inventors: Yueyun Ding, Xiaoling Ding, Zongjun Yin, Xudong Wu, Xiaodong Zhang, Xianrui Zheng, Zijing Ling, Qiong Chen, Yinhui Hou, Chengcheng Kong
  • Publication number: 20240102336
    Abstract: A control method for a charging port cover of a vehicle including a charging end assembly. The charging end assembly includes a charging port having a fast charging port and a slow charging port and a charging port cover having a fast charging port cover and a slow charging port cover. The method includes: when a charging port cover opening signal is received, controlling both the fast charging port cover and the slow charging port cover to be opened; when one of the fast charging port and the slow charging port is detected to be inserted with a plug-in end of a charging device, generating a charging port cover closing instruction; and controlling the charging port cover corresponding to the charging port into which the plug-in end is not inserted to be closed according to the charging port cover closing instruction.
    Type: Application
    Filed: December 8, 2023
    Publication date: March 28, 2024
    Inventors: Canlin ZHANG, Xiaoling ZHENG
  • Patent number: 11884691
    Abstract: Embodiments of the present application relate to functionalized N-acetylgalactosamine-analogs, methods of making, and uses of the same. In particular, mono or trivalent N-acetylgalactosamine analogs may be prepared by utilizing a wide variety of linkers containing functional groups. These functionalized N-acetylgalactosamine-analogs may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: January 30, 2024
    Assignee: Hongene Biotech Corporation
    Inventors: Wing C. Poon, Gang Zhao, Gengyu Du, Yun-Chiao Yao, Mufa Zou, Xiaoyang Guan, Xiaoling Zheng, David Yu, Ruiming Zou, Aldrich N. K. Lau
  • Publication number: 20230340000
    Abstract: Embodiments of the present application relate to functionalized N-acetylgalactosamine-analogs, methods of making, and uses of the same. In particular, mono or trivalent N-acetylgalactosamine analogs may be prepared by utilizing a wide variety of linkers containing functional groups. These functionalized N-acetylgalactosamine-analogs may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.
    Type: Application
    Filed: May 18, 2023
    Publication date: October 26, 2023
    Inventors: Wing C. POON, Gang ZHAO, Gengyu DU, Yun-Chiao YAO, Mufa ZOU, Xiaoyang GUAN, Xiaoling ZHENG, David YU, Ruiming ZOU, Aldrich N.K. LAU
  • Patent number: 11692001
    Abstract: Embodiments of the present application relate to functionalized N-acetylgalactosamine-analogs, methods of making, and uses of the same. In particular, mono or trivalent N-acetylgalactosamine analogs may be prepared by utilizing a wide variety of linkers containing functional groups. These functionalized N-acetylgalactosamine-analogs may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: July 4, 2023
    Assignee: Hongene Biotech Corporation
    Inventors: Wing C. Poon, Gang Zhao, Gengyu Du, Yun-Chiao Yao, Mufa Zou, Xiaoyang Guan, Xiaoling Zheng, David Yu, Ruiming Zou, Aldrich N. K. Lau
  • Patent number: 11649260
    Abstract: Embodiments of the present application relate to N-acetylgalactosamine-conjugated nucleosides. In particular, the N-acetylgalactosamine is installed on the nucleobase of the nucleosides through a wide variety of linkers. Methods of making N-acetylgalactosamine-conjugated nucleosides are also disclosed herein. N-acetylgalactosamine is a well-defined liver-targeted moiety and N-acetylgalactosamine-conjugated nucleosides may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: May 16, 2023
    Assignee: Hongene Biotech Corporation
    Inventors: Xiaoyang Guan, David Yu, Ruiming Zou, Xiaoling Zheng, John Liu, Aldrich N. K. Lau, Wing C. Poon, Gang Zhao, Gengyu Du, Yun-Chiao Yao
  • Publication number: 20230100220
    Abstract: Embodiments of the present application relate to functionalized N-acetylgalactosamine-analogs, methods of making, and uses of the same. In particular, mono or trivalent N-acetylgalactosamine analogs may be prepared by utilizing a wide variety of linkers containing functional groups. These functionalized N-acetylgalactosamine-analogs may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.
    Type: Application
    Filed: August 26, 2022
    Publication date: March 30, 2023
    Inventors: Wing C. POON, Gang ZHAO, Gengyu DU, Yun-Chiao YAO, Mufa ZOU, Xiaoyang GUAN, Xiaoling ZHENG, David YU, Ruiming ZOU, Aldrich N.K. LAU
  • Publication number: 20230034284
    Abstract: Embodiments of the present application relate to N-acetylgalactosamine-conjugated nucleosides. In particular, the N-acetylgalactosamine is installed on the nucleobase of the nucleosides through a wide variety of linkers. Methods of making N-acetylgalactosamine-conjugated nucleosides are also disclosed herein. N-acetylgalactosamine is a well-defined liver-targeted moiety and N-acetylgalactosamine-conjugated nucleosides may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.
    Type: Application
    Filed: June 16, 2022
    Publication date: February 2, 2023
    Inventors: Xiaoyang Guan, David Yu, Ruiming Zou, Xiaoling Zheng, John Liu, Aldrich N.K. Lau, Wing C. Poon, Gang Zhao, Gengyu Du, Yun-Chiao Yao
  • Publication number: 20230027257
    Abstract: The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
    Type: Application
    Filed: February 14, 2022
    Publication date: January 26, 2023
    Inventors: Wang SHEN, Jack MAUNG, Aimin ZHANG, Xiaoling ZHENG
  • Patent number: 11524956
    Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: December 13, 2022
    Assignee: Newgen Therapeutics, Inc.
    Inventors: Wang Shen, Aimin Zhang, Jack Maung, Xiaoling Zheng
  • Patent number: 11248013
    Abstract: The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: February 15, 2022
    Assignee: Rakovina Therapeutics Inc.
    Inventors: Wang Shen, Jack Maung, Aimin Zhang, Xiaoling Zheng
  • Publication number: 20210047303
    Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
    Type: Application
    Filed: March 27, 2020
    Publication date: February 18, 2021
    Inventors: Wang SHEN, Aimin ZHANG, Jack MAUNG, Xiaoling ZHENG
  • Publication number: 20200299315
    Abstract: The invention provides lor compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds arc potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
    Type: Application
    Filed: October 28, 2019
    Publication date: September 24, 2020
    Inventors: Wang SHEN, Jack MAUNG, Aimin ZHANG, Xiaoling ZHENG
  • Publication number: 20190382382
    Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
    Type: Application
    Filed: January 18, 2019
    Publication date: December 19, 2019
    Inventors: Wang SHEN, Aimin ZHANG, Jack MAUNG, Xiaoling ZHENG
  • Patent number: 10426762
    Abstract: The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: October 1, 2019
    Assignee: COCRYSTAL PHARMA, INC.
    Inventors: Sam S. Lee, Wang Shen, Xiaoling Zheng, Irina C. Jacobson
  • Publication number: 20180094010
    Abstract: The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
    Type: Application
    Filed: June 15, 2017
    Publication date: April 5, 2018
    Inventors: Wang SHEN, Jack MAUNG, Aimin ZHANG, Xiaoling ZHENG
  • Publication number: 20180093975
    Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
    Type: Application
    Filed: August 11, 2017
    Publication date: April 5, 2018
    Inventors: Wang SHEN, Aimin ZHANG, Jack MAUNG, Xiaoling ZHENG
  • Publication number: 20170273962
    Abstract: The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
    Type: Application
    Filed: June 9, 2017
    Publication date: September 28, 2017
    Inventors: Sam S. Lee, Wang Shen, Xiaoling Zheng, Irina C. Jacobson